Formulation Development
Sosei Heptares Receives $10-Million Milestone Payment in Discovery Collaboration With AbbVie Targeting Inflammatory Diseases
Sosei Group Corporation recently announced it has reached an important R&D milestone under its discovery collaboration with AbbVie, the global biopharmaceutical company, focused on inflammatory and autoimmune….
Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation & Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients With Advanced Solid Tumors
Indaptus Therapeutics, Inc. recently announced the initiation of INDP-D101, its first-in-human, open-label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound…
Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction & Progression Free Survival Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model
Starton Therapeutics Inc. recently announced results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant…
Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
Lantheus Holdings, Inc. recently announced a strategic collaboration with SonoThera, Inc. in which Lantheus’ microbubbles will be used in combination with SonoThera’s ultrasound-guided, nonviral, gene…
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-Derived Allogeneic CAR-NK Cell Therapy
Caribou Biosciences, Inc. recently announced target selection for CB-020, an induced pluripotent stem cell (iPSC)-derived allogeneic anti-ROR 1 (receptor tyrosine kinase like orphan receptor 1)…
UM171 Cell Therapy Demonstrates Improved Outcomes Compared to Cord & Matched Unrelated Donor Peripheral Blood Transplants in Real-World Setting
ExCellThera Inc. recently announced findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy in a Phase 1/2 trial to those treated with….
FDA Accepts Biogen Biologics License Application for Biosimilar Candidate Referencing ACTEMRA (tocilizumab)
Biogen Inc. recently announced the US FDA has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800, a biosimilar candidate referencing ACTEMRA (tocilizumab),…
Quotient Sciences Celebrates Grand Opening of New Drug Substance Facility with Official Ribbon Cutting
Quotient Sciences, the drug development and manufacturing accelerator, will hold an official ribbon cutting event in celebration of the grand opening of their new drug…
Catalent Opens One of the World’s Largest Commercial-Scale Cell Therapy Manufacturing Facilities at its European Center of Excellence for Cell Therapies in Belgium
Catalent recently announced the completion and opening of a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies in….
Metrion Biosciences & The KCNC1 Foundation Collaborate on Development of New Ion Channel Modulators for Ultra-Rare Genetic Disorder
Metrion Biosciences Limited and The KCNC1 Foundation recently announced a collaboration to progress a hit identification research project for small molecule modulators of the….
VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform
VYNE Therapeutics Inc. recently announced GB Patent No. 2597228, titled Compounds Comprising N-Methyl-2-Pyridone, And Pharmaceutically Acceptable Salts, has been granted by the United Kingdom’s Intellectual Property…
Esperion Announces CLEAR Cardiovascular Outcomes Trial Meets Primary Endpoint
Esperion recently announced the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial met its primary endpoint, demonstrating statistically significant risk reduction…
Summit Therapeutics Partners With Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
Summit Therapeutics Inc. recently announced a definitive agreement of its partnership with Akeso Inc. to in-license its breakthrough bispecific antibody, ivonescimab…..
Evonik Launches Plant-Based Squalene to Boost Vaccine Efficacy
Evonik has recently launched a non-animal-derived squalene suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene on the market…
Incannex Expands Intellectual Property Position Over IHL-42X
Incannex Healthcare Limited recently announced the filing of a provisional patent application directed to the use of IHL-42X for the treatment of Obstructive Sleep Apnoea….
Enzyvant Announces Merger With Altavant
Combined company has full range of capabilities required to advance bold science for rare diseases in immunology and cardiopulmonology….
Ocuphire Pharma Announces Submission of NDA for Eye Drops for Reversal of Mydriasis
Ocuphire Pharma, Inc. recently announced the submission of a New Drug Application (NDA) to the US FDA for Phentolamine Ophthalmic Solution 0.75% (Nyxol) for the…
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS
ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS….
RespireRx Enters Collaboration With National Institute for Neurological Disorders & Stroke to Advance its Lead GABAkine Toward Clinical Development
RespireRx Pharmaceuticals Inc. recently announced it has been accepted into the NIH HEAL Initiative NINDS Preclinical Screening Platform for Pain (PSPP) program. The company’s lead…
Ventyx Biosciences Announces Dosing of the First Patient in Phase 2 SERENITY Trial for the Treatment of Moderate-to-Severe Plaque Psoriasis
Ventyx Biosciences, Inc. recently announced the first patient has been dosed in a Phase 2 trial of its selective, allosteric TYK2 inhibitor VTX958 for the…
